325 related articles for article (PubMed ID: 30736861)
1. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
2. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
3. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
4. The Use of External Controls in FDA Regulatory Decision Making.
Jahanshahi M; Gregg K; Davis G; Ndu A; Miller V; Vockley J; Ollivier C; Franolic T; Sakai S
Ther Innov Regul Sci; 2021 Sep; 55(5):1019-1035. PubMed ID: 34014439
[TBL] [Abstract][Full Text] [Related]
5. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.
Kakkis ED; O'Donovan M; Cox G; Hayes M; Goodsaid F; Tandon PK; Furlong P; Boynton S; Bozic M; Orfali M; Thornton M
Orphanet J Rare Dis; 2015 Feb; 10():16. PubMed ID: 25757705
[TBL] [Abstract][Full Text] [Related]
8. Regulatory environment for novel therapeutic development in mitochondrial diseases.
Hirano M; Berardo A; Barca E; Emmanuele V; Quinzii C; Simpson CV; Engelstad K; Rosales XQ; Thompson JLP
J Inherit Metab Dis; 2021 Mar; 44(2):292-300. PubMed ID: 33368420
[TBL] [Abstract][Full Text] [Related]
9. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
10. Challenges of developing and conducting clinical trials in rare disorders.
Kempf L; Goldsmith JC; Temple R
Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
[TBL] [Abstract][Full Text] [Related]
11. Orphan drug development: the increasing role of clinical pharmacology.
Ahmed MA; Okour M; Brundage R; Kartha RV
J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):395-409. PubMed ID: 31338634
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the design of small population clinical trials.
Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
[TBL] [Abstract][Full Text] [Related]
13. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
14. Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications.
Lin X; Lee S; Scott J; Lin M
Ther Innov Regul Sci; 2021 Mar; 55(2):346-359. PubMed ID: 32955712
[TBL] [Abstract][Full Text] [Related]
15. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
16. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 2: data extrapolation, trial design, and pharmacokinetics.
Sun H; Vesely R; Nelson RM; Taminiau J; Szitanyi P; Isaac M; Klein A; Uzu S; Griebel D; Mulberg AE;
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):684-8. PubMed ID: 24866782
[TBL] [Abstract][Full Text] [Related]
17. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
18. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
Bannister JB
Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
[TBL] [Abstract][Full Text] [Related]
19. Advocacy groups and their role in rare diseases research.
Dunkle M; Pines W; Saltonstall PL
Adv Exp Med Biol; 2010; 686():515-25. PubMed ID: 20824463
[TBL] [Abstract][Full Text] [Related]
20. Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?
Richardson E; Daniel G; Joy DR; Kweder SL; Maloney DM; Raggio MJ; Jarow JP
Ther Innov Regul Sci; 2018 Nov; 52(6):793-798. PubMed ID: 29714587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
